The level of elastase 1 in feces was markedly decreased in all patients with tumors of the pancreatic head or its involvement before and after gastropancreatoduodenal resection and was close to normal in patients with retroperitoneal tumors not invading the pancreas. Serum elastase 1 concentrations were virtually the same in patients, normal subjects, and patients without signs of pancreatic involvement. The presence of elastase 1 in feces reflects adequate function of the pancreato-digestive anastomosis, while low concentrations of the enzyme indicate impaired function of the pancreas, presumably because of operation trauma and tumor process. Measurement of elastase 1 in feces is a highly informative and specific test for evaluation of pancreatic function in patients with pancreatic tumors, which can be used in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1023433509956 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Micronutrient Deficiencies in Heart Failure and Relationship with Exocrine Pancreatic Insufficiency.
Nutrients
December 2024
Department of Cardiology, University Medical Centre Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Background: Micronutrient deficiencies are common and play a significant role in the prognosis of many chronic diseases, including heart failure (HF), but their prevalence in HF is not well known. As studies have traditionally focused on causes originating within the intestines, exocrine pancreatic insufficiency (EPI) has been overlooked as a potential contributor. The exocrine pancreas enables the absorption of various (fat-soluble) micronutrients and may be insufficient in HF.
View Article and Find Full Text PDFPrescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia.
Pancreatology
December 2024
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Objective: To investigate the practices of clinicians prescribing pancreatic enzyme replacement therapy (PERT) for unresectable pancreatic cancer in Aotearoa New Zealand and Australia.
Methods: A mixed media advertising campaign was used to recruit appropriate clinicians to complete a questionnaire that collected demographic data, information regarding prescribed medication, and awareness of PERT guidelines.
Results: The study recruited 161 clinicians, with 93 and 68 respondents from Aotearoa New Zealand and Australia respectively.
Preanalytical and analytical factors affecting elastase quantitation in stool.
Clin Biochem
October 2024
ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address:
Exocrine pancreatic insufficiency (EPI) is a condition caused by a deficiency of exocrine pancreatic enzymes, resulting in malabsorption of nutrients. Clinical manifestations of EPI may include steatorrhea, weight loss, diarrhea, and abdominal pain. Although direct testing is the most sensitive and specific for EPI, these tests are invasive, time consuming, expensive, and not well standardized.
View Article and Find Full Text PDFBacteriophages isolated from mouse feces attenuates pneumonia mice caused by Pseudomonas aeruginosa.
PLoS One
July 2024
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Most of the current bacteriophages (phages) are mostly isolated from environments. However, phages isolated from feces might be more specific to the bacteria that are harmful to the host. Meanwhile, some phages from the environment might affect non-pathogenic bacteria for the host.
View Article and Find Full Text PDFClinical and Analytical Comparison of Monoclonal and Polyclonal Immunoassays for Fecal Pancreatic Elastase.
Diagnostics (Basel)
May 2024
Department of Laboratory Diagnostics, Children's Hospital Zagreb, 10000 Zagreb, Croatia.
Background: Numerous immunoassays have been commercialized to determine pancreatic elastase (PE) in feces in screening for exocrine pancreatic insufficiency (EPI), but how the different assays compare to one another is controversial, especially in the context that all methods use the same cut-off values for interpreting the results obtained on the presence or absence of EPI or the degree of insufficiency if it is present. Our aim was to analytically verify a new method for determining PE, compare the results with a previous method, and verify the declared cut-off values for interpretation of the results.
Methods: PE in the stool was assayed using a previous monoclonal enzyme-linked immunosorbent assay ("ScheBo ELISA") and a new polyclonal particle-enhanced turbidimetric immunoassay ("Bühlmann PETIA").
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!